A
17.67
0.22 (1.26%)
| Previous Close | 17.45 |
| Open | 17.24 |
| Volume | 2,440,056 |
| Avg. Volume (3M) | 2,511,177 |
| Market Cap | 2,220,801,024 |
| Price / Earnings (Forward) | 46.30 |
| Price / Sales | 3.95 |
| Price / Book | 19.25 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -28.83% |
| Operating Margin (TTM) | -49.96% |
| Diluted EPS (TTM) | -1.80 |
| Quarterly Revenue Growth (YOY) | -3.20% |
| Total Debt/Equity (MRQ) | 285.94% |
| Current Ratio (MRQ) | 4.08 |
| Operating Cash Flow (TTM) | -8.29 M |
| Levered Free Cash Flow (TTM) | 45.63 M |
| Return on Assets (TTM) | -14.20% |
| Return on Equity (TTM) | -103.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Apellis Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
0.3
| Analyst Consensus | 5.0 |
| Insider Activity | -2.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | 0.30 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 13.69% |
| % Held by Institutions | 104.60% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Citigroup, 194.28%) | Buy |
| Median | 38.50 (117.88%) | |
| Low | 19.00 (RBC Capital, 7.53%) | Hold |
| Average | 37.25 (110.81%) | |
| Total | 5 Buy, 3 Hold | |
| Avg. Price @ Call | 21.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 04 Aug 2025 | 37.00 (109.39%) | Buy | 24.26 |
| Cantor Fitzgerald | 01 Aug 2025 | 40.00 (126.37%) | Buy | 22.95 |
| Citigroup | 01 Aug 2025 | 52.00 (194.28%) | Buy | 22.95 |
| 29 Jul 2025 | 46.00 (160.33%) | Buy | 18.95 | |
| RBC Capital | 01 Aug 2025 | 19.00 (7.53%) | Hold | 22.95 |
| Raymond James | 01 Aug 2025 | 50.00 (182.97%) | Buy | 22.95 |
| Baird | 18 Jul 2025 | 50.00 (182.97%) | Buy | 19.47 |
| B of A Securities | 16 Jul 2025 | 24.00 (35.82%) | Hold | 19.75 |
| Morgan Stanley | 02 Jul 2025 | 26.00 (47.14%) | Hold | 17.82 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SULLIVAN TIMOTHY EUGENE | - | 26.91 | -42,729 | -1,149,837 |
| WATSON DAVID O. | - | 26.04 | -20,000 | -520,800 |
| Aggregate Net Quantity | -62,729 | |||
| Aggregate Net Value ($) | -1,670,637 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 26.62 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WATSON DAVID O. | Officer | 10 Sep 2025 | Sell (-) | 20,000 | 26.04 | 520,800 |
| SULLIVAN TIMOTHY EUGENE | Officer | 08 Sep 2025 | Automatic sell (-) | 32,729 | 26.91 | 880,737 |
| SULLIVAN TIMOTHY EUGENE | Officer | 08 Sep 2025 | Sell (-) | 10,000 | 26.91 | 269,100 |
| SULLIVAN TIMOTHY EUGENE | Officer | 08 Sep 2025 | Option execute | 15,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 31 Jul 2025 | Announcement | Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results |
| 28 Jul 2025 | Announcement | FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older |
| 24 Jul 2025 | Announcement | Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results |
| 01 Jul 2025 | Announcement | Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |